Stock Market & Financial Investment News

News Breaks September 12, 2012 06:43 EDT ARQL ArQule initiated with an Outperform at Burrill Burrill believes ArQule's oral inhibitor Tivantinib could be approved in 2013. The firm started shares with an Outperform rating and $10 price target. News For ARQL From The Last 14 Days Check below for free stories on ARQL the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 17, 2013 07:28 EDT ARQL Cambridge Healthtech Institute to host a conference Subscribe for More Information 06:03 EDT ARQL 1Globe Capital reports 6.4% passive stake in ArQule Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.